Cingulate Inc.
CING$19M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaKANSAS CITY
Clinical-stage pharmaceutical company developing ADHD treatments
Drugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
CING News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
CTx-1301 - Dexmethylphenidate 25mg
ADHD
CTx-1301-Dexmethylphenidate 12.5 mg (titration only)
ADHD
Dexmethylphenidate 5 Mg Oral Capsule, Extended Release
ADHD
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CTx-1301 - Dexmethylphenidate 25mg | Phase 3 | ADHD | - | - |
CTx-1301-Dexmethylphenidate 12.5 mg (titration only) | Phase 3 | ADHD | - | - |
Dexmethylphenidate 5 Mg Oral Capsule, Extended Release | Phase 2 | ADHD | - | - |
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply